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Abstract
Purpose Subcutaneous APF530 provides controlled sustained
release of granisetron to prevent acute (0–24 h) and delayed
(24–120 h) chemotherapy-induced nausea and vomiting
(CINV). This randomized, double-blind phase 3 trial compared
APF530 and palonosetron in preventing acute and delayed
CINV after moderately (MEC) or highly emetogenic chemo-
therapy (HEC).
Methods Patients receiving single-day MEC or HEC received
single-dose APF530 250 or 500 mg subcutaneously (SC)
(granisetron 5 or 10 mg) or intravenous palonosetron
0.25 mg. Primary objectives were to establish APF530
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noninferiority to palonosetron for preventing acute CINV
following MEC or HEC and delayed CINV following MEC
and to determine APF530 superiority to palonosetron for
preventing delayed CINV following HEC. The primary effi-
cacy end point was complete response (CR [using CI differ-
ence for APF530−palonosetron]). A lower confidence bound
greater than −15 % indicated noninferiority.
Results In the modified intent-to-treat population (MEC=
634; HEC=707), both APF530 doses were noninferior to
palonosetron in preventing acute CINV after MEC (CRs
74.8 % [−9.8, 9.3] and 76.9 % [−7.5, 11.4], respectively, vs.
75.0% palonosetron) and after HEC (CRs 77.7% [−11.5, 5.5]
and 81.3 % [-7.7, 8.7], respectively, vs. 80.7 % palonosetron).
APF530 500 mg was noninferior to palonosetron in
preventing delayed CINV after MEC (CR 58.5 % [−9.5,
12.1] vs. 57.2 % palonosetron) but not superior in preventing
delayed CINVafter HEC. Adverse events were generally mild
and unrelated to treatment, the most common (excluding
injection-site reactions) being constipation.
Conclusions A single subcutaneous APF530 injection offers
a convenient alternative to palonosetron for preventing acute
and delayed CINVafter MEC or HEC.
Keywords Cancer . Chemotherapy-induced nausea and
vomiting (CINV) . Extended-release . Granisetron .
Subcutaneous . APF530
Introduction
Supportive care is essential for patients with cancer receiving
chemotherapy. Advances in understanding the physiology of
emesis led to the development of receptor-targeted antiemetics
(5-hydroxytryptamine 3 [5-HT3] antagonists, neurokinin-1
[NK-1] antagonists) and resulted in evidence-based guidelines
for prevention of chemotherapy-induced nausea and vomiting
(CINV) for acute (within 24 h of chemotherapy administra-
tion) and delayed (24–120 h after chemotherapy administra-
tion) phases [1–3].
An important risk factor for CINV is the emetogenicity of
the chemotherapy regimen, first classified by the Hesketh
algorithm [4]. Clinical practice guidelines [1–3] recommend
a combination of a 5-HT3 antagonist, dexamethasone, and an
NK-1 antagonist to prevent CINV after administration of
highly emetogenic chemotherapy (HEC). For moderately
emetogenic chemotherapy (MEC), guidelines differ some-
what depending on the chemotherapy regimen but generally
recommend a 5-HT3 antagonist plus dexamethasone (plus a
NK-1 antagonist for select patients).
Nevertheless, CINV prevention (especially delayed CINV)
remains a significant problem and is considerably
underestimated by physicians and nurses [5]. Consequently,
strategies to improve CINV prevention (especially delayed)
are needed. First-generation 5-HT3 antagonists (ondansetron,
granisetron, dolasetron [oral]) are administered daily because
of their short half-lives, usually on day 1 of chemotherapy
only [1, 3, 6]. They may be administered on days 2 and 3 to
control delayed CINV, but their efficacy and cost-
effectiveness in this setting are questionable [7]. Palonosetron,
a second-generation 5-HT3 antagonist with a longer half-life
(∼40 h), can be administered on day 1 of chemotherapy only
[1, 3, 8–12]. Several hypotheses, based on preclinical studies,
have been proposed for its mechanism of action, including 5-
HT3 receptor internalization and prolonged inhibition of 5-
HT3 receptor function that continues after palonosetron has
dissociated from the cell surface [13, 14].
APF530 is a new, subcutaneously (SC) administered poly-
meric formulation of granisetron that was developed to pro-
vide slow, controlled, and sustained release of granisetron to
prevent both acute and delayed CINV associated with MEC
and HEC [15]. APF530 comprises 2 % granisetron and a
polymer vehicle of tri(ethylene glycol) poly(orthoester)
(TEG-POE) that undergoes controlled hydrolysis, resulting
in slow, controlled, and sustained drug release. The novel
biodegradable polymeric excipient is hydrolyzed in vivo, gen-
erating nontoxic biodegradable metabolites. This
Biochronomer™ drug delivery system (Heron Therapeutics,
Inc., Redwood City, CA) allows therapeutic levels of
granisetron to be maintained for >5 days with a single subcu-
taneous injection. In clinical studies in patients undergoing
chemotherapy, single-dose APF530 (5–15 mg granisetron)
administered SC in the abdomen provided circulating levels
of granisetron within 30 min, a maximum plasma concentra-
tion at ∼24 h, and sustained therapeutic levels for >120 h.
In this phase 3 noninferiority trial, the clinical efficacy of
APF530 250 and 500 mg SC (containing granisetron 5 and
10 mg, respectively) was compared with that of the approved
dose of palonosetron (0.25 mg intravenously [IV]) for pre-
vention of acute and delayed CINV following single-day
administration of MEC or HEC in patients with cancer.
Methods
Patients
Eligible patients were men or women ≥18 years old with
histologically or cytologically confirmed malignancy and
scheduled to receive single-day MEC or HEC according to
then-applicable Hesketh criteria [4, 16]. All patients provided
written informed consent. At least 7 days before study drug
administration, patients discontinued antiemetics and system-
ic corticosteroids (including dexamethasone). Planned chemo-
therapy was to be ≤4 h (excluding monoclonal antibodies).
Patients could be chemotherapy naïve or nonnaïve and had to
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have Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ≤2.
Key exclusion criteria included gastrointestinal cancers or
intestinal obstruction, head and neck cancers, or primary brain
tumors or metastases with the potential to affect nausea and
vomiting centers in the brain; receipt of chemotherapy during
the 7 days before study drug administration; no vomiting or
more than mild nausea within 24 h before study drug admin-
istration; a QTc interval >500 ms or a >60 ms change from
baseline; or other cardiac abnormality predisposing to signif-
icant arrhythmia.
Study design and treatments
This prospective, multicenter, randomized, double-blind, dou-
ble-dummy, parallel-group phase 3 trial (clinicaltrials.gov
identifier: NCT00343460) was approved by the Institutional
Review Board or Independent Ethics Committee at each cen-
ter and conducted according to the Declaration of Helsinki.
Enrolled patients received single-day MEC or HEC, de-
fined by the Hesketh algorithm [4, 16]. Chemotherapeutic
agents causing emesis in <10 % of patients were defined as
level 1 agents, 10–30 % as level 2, 30–60 % as level 3, 60–
90 % as level 4, and >90 % as level 5. For combination
regimens, the most emetogenic agent was identified (as level
1–5), then the relative contribution of each additional agent
was added as follows: a level 1 agent did not contribute to
emetogenicity; one or more level 2 agents increased
emetogenicity by one level greater than the most emetogenic
agent; and one or more level 3 or 4 agents increased
emetogenicity by one level per agent more than the most
emetogenic agent.
Patients were stratified according to their chemotherapy
emetogenicity (MEC or HEC) and randomized 1:1:1 to re-
ceive APF530 250 mg SC (granisetron 5 mg) plus placebo IV;
APF530 500 mg SC (granisetron 10 mg) plus placebo IV; or
palonosetron IV 0.25 mg plus placebo SC (Fig. 1) prior to
chemotherapy. Isotonic saline was used for placebo SC injec-
tions and intravenous infusions. After cycle 1, all patients were
invited to continue in the study. If they consented, they were
rerandomized to maintain blinding, but only patients who
received palonosetron in cycle 1 were actually randomized
1:1 to receive APF530 250 or 500 mg SC for ≤3 subsequent
cycles.
On day 1, study drug was administered 30–60 min before
single-day MEC or HEC. All subcutaneous injections were
administered abdominally; a local anesthetic could be adminis-
tered beforehand. Protocol-specified doses of dexamethasone
were administered 30–90 min before chemotherapy (8 mg IV
for MEC, 20 mg IV for HEC). On days 2–4, oral dexametha-
sone 8 mg twice daily was prescribed to patients receiving
HEC. Rescue medications were allowed as needed. APF530
SC was administered in ≤4 treatment cycles separated by 7 to
28 days (±3); palonosetron IV was discontinued after cycle 1.
Objectives and efficacy evaluations
The primary objectives were to establish, during cycle 1,
noninferiority of APF530 SC to palonosetron IV in preventing
acute CINV (0–24 h) following MEC or HEC administration,
noninferiority of APF530 SC to palonosetron IV in preventing
delayed CINV (24–120 h) following MEC administration,
and superiority of APF530 SC to palonosetron IV in
preventing delayed CINV (24–120 h) following HEC admin-
istration. Secondary objectives included evaluation of efficacy
over the entire (0–120 h) period during cycle 1 and evaluation
of safety and tolerability of APF530 SC.
The primary efficacy end point was the percentage of
patients achieving a complete response (CR; no emetic epi-
sodes and no use of rescue medications) during the acute (0–
24 h) and delayed (24–120 h) phases after chemotherapy cycle
1. Secondary end points included safety and percentage of
patients with CR over the entire (0–120 h) period during cycle
1, both of which are reported here. Other secondary end points
(not reported) included percentages of patients with complete
control (CC; CR with no more than mild nausea) and total
response (TR; CR with no nausea) during the acute and
delayed phases in cycle 1; assessment of APF530 SC phar-
macokinetics in a subset of patients receiving MEC or HEC
during cycle 1; and measurement of cardiac safety using
electrocardiographicmonitoring during cycle 1. Efficacymea-
sures were determined from diaries, in which patients record-
ed emetic episodes, rescue medication, and severity of nausea
for each 24-h period after chemotherapy.
At the time that this study was conducted, chemotherapy
regimens containing cyclophosphamide plus anthracyclines
were classified as moderately emetogenic [4, 16]. However,
in 2011, the American Society of Clinical Oncology
reclassified cyclophosphamide plus anthracycline regimens
as highly emetogenic in its antiemesis guidelines [2]. Conse-
quently, at the request of the US Food and Drug Administra-
tion (FDA), a post hoc analysis of efficacy end points was
Fig. 1 Study design. First randomization: all patients (superscript a).
Second randomization: palonosetron patients (superscript b)
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undertaken with these combination regimens reclassified as
HEC.
Safety evaluations
Adverse events (AEs; based on standard toxicity
criteria) and serious AEs (SAEs) were evaluated during
each treatment cycle, including type, duration, severity
(mild, moderate, severe), and investigator’s opinion in
relation to study drug. Physical examinations, vital
signs, and clinical laboratory parameters were also
assessed.
Statistical analysis
The planned sample size was 1,404 patients, 669 in the
MEC stratum (n=223 per treatment group for cycle 1)
and 735 in the HEC stratum (n=245 per treatment
group in cycle 1). For the MEC stratum, sample size
was based on the assumption of a CR of 65 % in any
treatment group and a difference of at least 15 % in
CR. For the HEC stratum, sample size was based on the
assumption of a CR of 50 % in any treatment group
and a difference of at least 15 % in CR.
In the primary efficacy analysis, noninferiority was
tested for six comparisons: two APF530 SC doses for
both acute and delayed CR in patients receiving MEC
and for acute CR in patients receiving HEC. Superiority
was tested between the APF530 SC doses and
palonosetron for delayed CR in patients receiving
HEC. To adjust for the effect of multiple comparisons,
analyses used Hochberg’s sharper Bonferroni procedure,
a stepwise multistage approach in which the level of
confidence is increased at each successive stage [17]. At
each stage, noninferiority was demonstrated when the
lower bound of the confidence interval (CI) for CR for
the difference between APF530 and palonosetron
(APF530−palonosetron) was greater than −15 %, and
superiority was demonstrated when the lower bound of
the CI was greater than 0 %; the noninferiority margin
of 15 % was selected as it was the same margin used in
palonosetron noninferiority clinical trials [8–10]. Treat-
ment comparisons were based on Fisher’s exact test.
Efficacy analyses were performed separately for MEC and
HEC strata and based on a modified intent-to-treat (mITT)
population, comprising all randomized patients who received
study drug and had postbaseline efficacy data. The safety
population comprised all patients who were randomized and
received study drug.
Quantitative variables were summarized by sample
size, mean, median, standard deviation (SD), minimum,
and maximum. Qualitative variables were summarized
by patient number and percentage. Unless otherwise
indicated, statistical significance was reached if the
two-sided p value was <0.05.
Results
Patient characteristics
The study was conducted between June 2006 and August
2008 at 103 centers in the USA, India, and Poland. Of 1,428
randomized patients, 33 did not receive study drug and were
excluded, leaving 1,395 patients evaluable for efficacy and
safety (n=653, MEC; n=742, HEC; defined by Hesketh
criteria) [4]. The disposition of patients by study drug
(APF530 250 or 500 mg SC, palonosetron 0.25 mg IV) and
by MEC and HEC for cycle 1 is shown in Fig. 2. In total, 639
patients (97.9 %) receiving MEC and 727 patients (98.0 %)
receiving HEC completed cycle 1. The most common reasons
for discontinuation were loss to follow-up (n=10, MEC; n=3,
HEC), withdrawal of consent (n=2, MEC; n=2, HEC), and
death (n=1, MEC; n=3, HEC). Of 1,341 patients who com-
pleted cycle 1, 1,043 (76.4 %) were rerandomized to APF530
250 or 500 mg SC prior to cycle 2. The most common MEC
regimen was based on cyclophosphamide plus an
anthracycline (56.0 % of patients), and the most common
HEC regimen was based on carboplatin plus a taxane
(40.3 %) (Table 1).
Baseline demographics and clinical characteristics (mITT
population) were similar across all treatment arms and across
both MEC and HEC strata (Table 2). Most patients were
women (62.8–87.7 % across emetogenicity strata and treat-
ment arms), and mean age ranged from 54.8 to 58.1 years. The
most common tumor types were breast cancer (63.3–69.5 %)
in the MEC stratum and lung (25.4–32.8 %) and breast can-
cers (25.4–27.6 %) in the HEC stratum. Overall, 319 patients
(48.9 %) receiving MEC and 426 patients (57.4 %) receiving
HEC had received prior chemotherapy.
Primary efficacy analysis
Results presented here are for the original prespecified analy-
sis, in which chemotherapy emetogenicity was determined
using Hesketh criteria [4]. In cycle 1, both APF530 250 and
500 mg SC were noninferior to palonosetron, as assessed by
CR, in the control of acute CINV after MEC, with CRs
(97.5 % CI difference vs. palonosetron) of 74.8 % (−9.8,
9.3) and 76.9 % (−7.5, 11.4), respectively, versus 75.0 % for
palonosetron (Fig. 3a). The result was similar for patients
receiving HEC, with acute CRs (98.33 % CI difference vs.
palonosetron) of 77.7 % (−12.1, 6.1) and 81.3 % (−8.2, 9.3)
for APF530 250 and 500 mg SC, respectively, versus 80.7 %
for palonosetron (Fig. 3b).
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APF530 500 mg SC also was noninferior to palonosetron
in preventing delayed CINVafter MEC, with a CR of 58.5 %
(−9.5, 12.1) versus 57.2 % for palonosetron (Fig. 3a). Supe-
riority of APF530 250 or 500 mg SC versus palonosetron
0.25 mg IV in preventing delayed CINVafter HEC in cycle 1
was not achieved, although CR rates were similar for APF530
500 mg SC and palonosetron 0.25 mg IV (CRs 67.1 vs.
64.3 % [−5.8, 11.3], respectively) (Fig. 3b).
Secondary efficacy analyses
A secondary efficacy objective was evaluation of APF530 SC
efficacy over the entire (0–120 h) period during cycle 1. After
administration of MEC, overall CRs (95 % CI difference vs.
palonosetron) with APF530 250 and 500 mg SC were 48.6 %
(−2.9, 6.2) and 53.8 % (−7.8, 11.4), respectively, versus
51.9 % for palonosetron 0.25 mg IV.
After administration of HEC, CRs (95 % CI difference vs.
palonosetron) with APF530 250 and 500 mg SC were 57.6 %
(−11.8, 6.1) and 63.3 % (−5.9, 11.6), respectively, versus
60.5 % for palonosetron 0.25 mg IVover the entire treatment
period (0–120 h).
Post hoc analysis of efficacy
In a post hoc analysis, patients receiving chemotherapy
regimens whose antiemetic risk had been revised ac-
cording to updated antiemetic practice guidelines, nota-
bly cyclophosphamide plus anthracyclines (reclassified
from MEC to HEC) and carboplatin-based regimens
(reclassified from HEC to MEC), were reclassified at
the request of the FDA [2]. The results of this reanal-
ysis showed no notable statistical or clinical differences
in response rates between APF530 and palonosetron.
Fig. 2 Patient disposition during cycle 1. According to Hesketh criteria [4] (superscript a). Safety population (superscript b)
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Safety and tolerability
The safety population comprised all patients (MEC and HEC)
who were randomized and received study drug (n=1,395).
Safety analyses were conducted on the combined MEC and
HEC populations and are presented for cycle 1 only (Table 3).
In cycle 1, 464 patients received APF530 250 mg SC, 468
received APF530 500 mg SC, and 463 received palonosetron
0.25 mg IV. Overall, AEs were generally mild and most were
considered unrelated to treatment. Excluding injection-site
reactions (ISRs), the most common AE was constipation
(occurring in 13.4–15.6 % of patients across all groups),
followed by fatigue (in 11.9–14.1 % of patients). Excluding
ISRs, the most frequent treatment-related AEs were mild
constipation (in 2.6–3.2 % of patients across all groups) and
mild headache (in 0.6–2.4% of patients). Excluding ISRs, two
patients had treatment-related AEs that led to study discontin-
uation in cycle 1: moderate dyspepsia in the APF530 250 mg
SC group and mild drug hypersensitivity in the APF530
500 mg SC group. Severe treatment-related AEs occurred in
15 patients, including 4 (0.9 %) in the APF530 250 mg SC
group, 6 (1.3 %) in the APF530 500 mg SC group, and 5
(1.1 %) in the palonosetron 0.25 mg IV group. There were no
significant differences between treatment groups in
percentages of patients who had AEs, percentages of patients
who discontinued because of a treatment-related AE, or se-
verity of treatment-related AEs.
Excluding ISRs, only one patient (0.2 %) in the APF530
250 mg SC group experienced a serious treatment-related AE
(pulmonary embolism), 16 days after receiving study medica-
tion; the event was considered possibly related to treatment,
and the patient was withdrawn from the study. Eleven patients
died in cycle 1: seven receiving APF530 250 mg SC, two
receiving APF530 500 mg SC, and two receiving
palonosetron 0.25 mg IV; but none of the deaths was consid-
ered to be related to treatment.
ISRs occurred in all treatment groups (Table 3). The most
common ISR during cycle 1 was bruising (in 9.1–19.9 % of
patients across all treatment groups), followed by erythema
(3.5–10.9% of patients) and nodules (0.6–10.7% of patients).
Treatment-related ISRs were more frequent in the APF530
groups than in the palonosetron group, but were generally
mild and resolved over time; the most commonly reported
treatment-related ISR was bruising. There were no severe
ISRs in cycle 1, and no patients discontinued therapy as a
result of an ISR.
There were no notable changes in physical examination or
clinical laboratory parameters.
Discussion
In this study, one of the largest prospective, randomized trials
conducted in CINV to date, APF530 250 and 500 mg SC
(containing granisetron 5 and 10 mg, respectively) demon-
strated noninferiority to palonosetron 0.25 mg IV in control-
ling acute CINV in patients who received MEC or HEC, as
determined by CR. APF530 500 mg SC was also noninferior
to palonosetron in preventing delayed CINV in patients re-
ceiving MEC. Furthermore, APF530 SC demonstrated anti-
emetic efficacy over the entire 120-h period after MEC or
HEC comparable to that of palonosetron. These results were
achieved in a patient population with a variety of cancer types
and receiving a range of chemotherapy regimens. The safety
profiles of both APF530 SC doses were similar to that of
palonosetron and consistent with previous clinical experience
with granisetron in the CINV setting [18, 19]. ISRs occurred
across all treatment groups, but were generally mild and
resolved by the end of the study. Thus, APF530 SC appears
to add an option to the existing formulations of granisetron
(IV, oral, and transdermal), providing sustained release of the
drug for prevention of both acute and delayed CINV in pa-
tients receiving MEC or HEC.
Limitations of this study include the fact that, at the time
the study was designed, palonosetron did not have an
established benefit in preventing delayed CINV in patients
Table 1 Summary of the most common moderately (MEC) and highly
(HEC) emetogenic chemotherapy regimens administered during cycle 1
(mITT population)

















Carboplatin without taxane 64 9.1
Dacarbazine-based 32 4.5
Oxaliplatin-based 17 2.4
Other combinations 9 1.3
Total 707 100.0
According to Hesketh criteria [4]
mITT modified intent to treat
a Some regimens appear in both categories depending on the doses
administered
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receiving HEC, so a noninferiority margin could not be set. In
addition, some criteria used to classify regimens as MEC or
HEC have been updated since the study was conducted.
Notably, regimens containing cyclophosphamide plus
anthracyclines classified as MEC in this study are now con-
sidered to be HEC, and carboplatin-based regimens classified
as HEC in this study are now considered to be MEC [1–4].
Assigning emetic risk of chemotherapy agents can be contro-
versial, and this is illustrated in the current study. Few che-
motherapy agents have been prospectively evaluated to deter-
mine their true emetic rate when antiemetics are not given. All
rating scales are based on expert consensus, rather than on true
high-quality evidence. The Hesketh classification was a dili-
gent effort to try to place combination chemotherapy, rather
Fig. 3 Complete response during
acute and delayed CINV phases
with APF530 250 and 500 mg SC
and palonosetron (PALO) 0.25mg
IV after administration of aMEC
and bHEC (according to Hesketh
criteria [4]) in cycle 1 (modified
intent-to-treat population)
Table 3 Treatment-emergent adverse events, by relationship to treatment, reported by ≥5 % of patients receiving APF530 SC and palonosetron IV in
cycle 1 (safety population)
AFP530 250 mg SC APF530 500 mg SC Palonosetron 0.25 mg IV
N=464 N=468 N=463
Related, n (%) Not related, n (%) Related, n (%) Not related, n (%) Related, n (%) Not related, n (%)
Preferred terma
Asthenia 3 (0.6) 21 (4.5) 0 22 (4.7) 3 (0.6) 27 (8)
Constipation 20 (4.3) 44 (9.5) 21 (4.5) 52 (11.1) 14 (3.0) 48 (10.4)
Diarrhea 6 (1.3) 46 (9.9) 5 (1.1) 40 (8.5) 5 (1.1) 35 (7.6)
Fatigue 6 (1.3) 59 (12.7) 5 (1.1) 61 (13.0) 3 (0.6) 52 (11.2)
Headache 13 (2.8) 19 (4.1) 13 (2.8) 36 (7.7) 9 (1.9) 38 (8.2)
Insomnia 3 (0.6) 18 (3.9) 0 25 (5.3) 0 11 (2.4)
Nausea 3 (0.6) 58 (12.5) 4 (0.9) 61 (13.0) 3 (0.6) 40 (8.6)
Injection-site reactions
Bruising 60 (12.9) 18 (3.9) 73 (15.6) 20 (4.3) 30 (6.5) 12 (2.6)
Erythema 28 (6.0) 5 (1.1) 38 (8.1) 13 (2.8) 13 (2.8) 3 (0.6)
Nodules 19 (4.1) 3 (0.6) 44 (9.4) 6 (1.3) 3 (0.6) 0
Pain 14 (3.0) 3 (0.6) 27 (5.8) 6 (1.3) 6 (1.3) 2 (0.4)
IV intravenously, SC subcutaneously
a A patient with more than one event represented by a given preferred term was counted once within each relatedness category that applied within that
preferred term
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than just single agents, into a useful system. As with all emetic
rating systems, it has limitations. Paradoxically, as seen in the
results of the current study, emetic control for all randomized
arms was somewhat higher in patients receiving HEC than it
was for those receiving MEC, according to the Hesketh sys-
tem. Limitations of current criteria used in treatment guide-
lines can be seen in the fact that groups have reclassified
emetic risk even of older chemotherapy agents (such as cy-
clophosphamide plus anthracyclines) more than a decade after
first listing these agents [1–3]. It was appropriate in this study
to give results by older and newer risk criteria, as requested by
the FDA. However, it is notable that a post hoc analysis
reclassifying patients according to the new antiemetic risk
criteria showed no notable statistical or clinical differences
in efficacymeasures between APF530 and palonosetron; so, it
did not alter the conclusions. Moreover, antiemetic guidelines
updated after this study was initiated [1–3] now recom-
mend the use of aprepitant as CINV prophylaxis in
patients receiving HEC.
To date, several large randomized trials have demonstrated
that palonosetron is at least as effective as ondansetron [8, 10],
dolasetron [9], and granisetron [11] in preventing CINV in
patients receiving MEC or HEC. However, in the current trial,
a new subcutaneous formulation of granisetron was
noninferior to palonosetron (an agent broadly recommended
as the preferred 5-HT3 antagonist in treatment guidelines
[1–3]), in the control of acute CINV in patients receiving
MEC or HEC and delayed CINV in patients receiving MEC.
It has been postulated that the superiority of palonosetron over
first-generation agents is in part due to its unique characteris-
tics, including cooperative interactions with substance P and
the NK-1 receptor pathway [20]. Our findings of noninferior-
ity of this granisetron formulation to palonosetron appear to
question this hypothesis. From the results of this study, it
appears that both APF530 and palonosetron provide good
antiemetic control in the settings tested, and oral palonosetron
was recently reported to be noninferior to palonosetron IV in
preventing acute CINV in patients receiving MEC [21]. The
convenience of a single SC injection of APF530 provides an
alternative option to palonosetron IV for the prevention of
CINV. Post hoc analyses may provide further insights into the
efficacy of APF530 SC and the effects of sex, age, type of
chemotherapy regimen administered, and prior therapies. Fur-
ther studies may investigate the potential for APF530 in other
clinical situations where sustained antiemetic activity is de-
sired, such as during multiday chemotherapy, in patients re-
ceiving radiation therapy, in patients who are unable to toler-
ate oral antiemetics, in combination with aprepitant and other
NK-1 antagonists, and in the postoperative setting.
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